脂必妥与洛伐他汀用于治疗高胆固醇血症的对比分析  

Comparison of zhibituo and lovastatin in the treatment of hyperlipidemia

作　　者：陈巧云[1] 魏水易[1] 陆晓和[2] 

机构地区：[1]第二军医大学药学院,上海200433 [2]南京军区南京总医院药品科,江苏南京210002

出　　处：《医学研究生学报》2004年第3期233-235,239,共4页Journal of Medical Postgraduates

摘　　要：目的 :比较脂必妥与洛伐他汀治疗高胆固醇血症的疗效、安全性和经济性。　方法 :检索相关文献 ,对报道中符合要求的脂必妥临床试验结果进行Meta分析 ,并与洛伐他汀进行对比分析 ;同时采用专家评分法对脂必妥和洛伐他汀从六个方面进行总体评价。　结果 :Meta分析结果表明 ,脂必妥降低三酰甘油和升高高密度脂蛋白作用较洛伐他汀强 ,对老年患者的严重药物不良反应少 ,价格低 ,脂必妥与洛伐他汀的专家评分结果差异无显著性意义。　结论 :两种药物均为治疗高胆固醇血症的有效药物 ,脂必妥用于轻中度混合性血脂升高的老年患者较安全而且经济适用。Objective:To compare the efficacy, safety and economics of zhibituo and lovastatin in the treatment of hyperlipidemia. Methods:Searching medical references were done, The qualified results of clinical trials were Meta-analysed for evaluating the efficacy of zhibituo comparing with lovastatin. The characters of zhibituo and lovastatin were also compared through scoring by senior physicians. Results:The results of Meta-analysis showed that zhibituo had stronger effects on lowering TG and elevating HDL.It had less severe ADR for old people and cost less than lovastatin. The results of physicians-scoring records showed no significant difference between these two drugs. Conclusion:Zhibituo and lovastatin both are potential lipid-lowering agents. zhibituo is safer and more cost-effective for old people with mild to moderate elevated serum LDL level.

关 键 词：脂必妥 洛伐他汀 药物评价 

分 类 号：R589.2[医药卫生—内分泌]